Xilio Therapeutics, Inc. is a clinical-stage biotechnology company developing tumor-activated immuno-oncology (I-O) therapies to improve cancer treatment outcomes without the systemic side effects of current I-O treatments. Using its proprietary platform, Xilio advances a pipeline of novel, tumor-activated clinical and preclinical I-O molecules, including cytokines, antibodies (bispecifics), and immune cell engagers. Its product pipeline features XTX101, XTX301, XTX202, XTX501, and other tumor-activated bispecific molecules and immune cell engagers, with XTX101 being an investigational anti-CTLA-4 monoclonal antibody. The XLO YTD return is shown above.
The YTD Return on the XLO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether XLO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XLO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|